MaxCyte Overview

  • Founded
  • 1998

Founded
  • Status
  • Public

  • Employees
  • 84

Employees
  • Stock Symbol
  • MXCT

Stock Symbol
  • Share Price
  • $5.76

  • (As of Friday Closing)

MaxCyte General Information

Description

MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which used blood cells instead of traditional chemical methods to transport medical gene therapies to targeted sites, increasing their safety and efficacy. The company technology finds its use in biotechnology and pharmaceutical firms engaged in cell therapy, including gene editing and immuno-oncology and in drug discovery, development, and biomanufacturing. Its products include MaxCyte STX, VLX, and GT. The company application includes Cell/Gene Therapy, Protein Production, Cell-based Assays, Gene Editing, Cell Line Development, and Viral Vectors/Vaccines. It acquires its income principally from the sale or lease of instruments and processing assemblies.

Contact Information

Website
www.maxcyte.com
Formerly Known As
TheraMed
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
LON
Primary Office
  • 22 Firstfield Road
  • Suite 110
  • Gaithersburg, MD 20878
  • United States
+1 (301) 000-0000

MaxCyte Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MaxCyte Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.76 $5.87 $3.46 - $17.09 $586M 102M 47.2K -$0.20

MaxCyte Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 274,360 772,035 523,497 79,149
Revenue 41,486 33,894 26,169 21,621
EBITDA (18,479) (16,765) (10,009) (11,806)
Net Income (19,882) (19,082) (11,816) (12,895)
Total Assets 289,777 284,120 51,780 29,985
Total Debt 14,492 5,682 6,966 7,211
Public Fundamental Data provided by Morningstar, Inc. disclaimer

MaxCyte Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.

Request a free trial

MaxCyte Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.

Request a free trial

MaxCyte Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
MaxCyte Inc operates in the United States healthcare sector. It develops proprietary electroporation technology, which u
Drug Discovery
Gaithersburg, MD
84 As of 2021
00000
000000000 00000

000 00

t labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris
0000000000000
Johnson City, TN
000000000000

000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut
0000 000000000
Menlo Park, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MaxCyte Competitors (25)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
PPA Research Group Private Equity-Backed Johnson City, TN 000000000000
0000000000 Formerly VC-backed Menlo Park, CA 000 00000 00000000 00000
0000000 Formerly VC-backed Redwood City, CA 000 00000 000000 - 000 00000
00000 Corporation San Diego, CA 00 00000 00000000 00000
00000000 Formerly VC-backed San Diego, CA 00000 00000 000000&0
You’re viewing 5 of 25 competitors. Get the full list »

MaxCyte Patents

MaxCyte Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20210348109-A1 Systems and methods for electroporation Pending 11-May-2020 000000000
CA-2982759-A1 Methods and compositions for modifying genomic dna Pending 13-Apr-2015 0000000000
EP-3283635-A1 Methods and compositions for modifying genomic dna Granted 13-Apr-2015 0000000000
JP-2018512162-A Methods and compositions for modifying genomic dna Granted 13-Apr-2015 0000000000
US-20180112235-A1 Methods and compositions for modifying genomic dna Pending 13-Apr-2015 C12N15/907
To view MaxCyte’s complete patent history, request access »

MaxCyte Executive Team (18)

Name Title Board Seat Contact Info
Douglas Doerfler Founder, Chief Executive Officer, President & Board Member
Ronald Holtz Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Cenk Sumen Ph.D Chief Scientific Officer
Kevin Gutshall Vice President, Corporate Business Development
You’re viewing 4 of 18 executive team members. Get the full list »

MaxCyte Board Members (14)

Name Representing Role Since
Arthur Mandell Self Board Member 000 0000
Douglas Doerfler MaxCyte Founder, Chief Executive Officer, President & Board Member 000 0000
J. Thompson Ph.D MaxCyte Chairman & Board Member 000 0000
John Johnston MaxCyte Board Member 000 0000
Rekha Hemrajani Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

MaxCyte Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MaxCyte Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore MaxCyte‘s full profile, request access.

Request a free trial